

# CHINA MEDICAL (INTERNATIONAL) GROUP LIMITED

(Incorporated in the Republic of Singapore)  
(Company Registration No. 200505118M)

---

## PROPOSED RENOUNCEABLE AND NON-UNDERWRITTEN RIGHTS CUM WARRANTS ISSUE – LODGEMENT AND DESPATCH OF OFFER INFORMATION STATEMENT AND INDICATIVE TIMETABLE OF KEY EVENTS

---

*Unless otherwise defined, all capitalised terms used in this announcement shall bear the same meanings as ascribed to them in the Company's Offer Information Statement dated 3 October 2017 and the previous announcements dated 31 March 2017, 7 June 2017, 18 September 2017 and 25 September 2017 in relation to the proposed renounceable and non-underwritten rights cum warrants issue of up to 10,107,788,721 new ordinary shares in the capital of the Company with up to 10,107,788,721 free detachable warrants each carrying the right to subscribe for one (1) new ordinary share capital of the Company, on the basis of three (3) rights shares for every one (1) existing ordinary share in the capital of the Company held by shareholders as at the books closure date, and one (1) warrant for one (1) rights shares subscribed, fractional entitlements to be disregarded (the "Offer Information Statement").*

*Any reference to the time of day and date herein shall be a reference to Singapore time and date, respectively.*

### 1. LODGEMENT AND DESPATCH OF THE OFFER INFORMATION STATEMENT

The Board of Directors ("**Directors**") of China Medical (International) Group Limited (the "**Company**", and together with its subsidiaries, the "**Group**") wishes to announce that the Offer Information Statement in relation to the Rights cum Warrants Issue, together with the accompanying documents, have been lodged with the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") (acting as agent on behalf of the Monetary Authority of Singapore) on 3 October 2017. A copy of the Offer Information Statement is attached hereto.

The Offer Information Statement, together with a copy of the application and acceptance form for Rights Shares with Warrants and Excess Rights Shares with Warrants (the "**ARE**") and the provisional allotment letter (the "**PAL**"), as the case may be, will be despatched to Entitled Shareholders on or around 6 October 2017.

For practical reasons and in order to avoid any violation of the securities legislation applicable in jurisdictions other than Singapore, the Offer Information Statement and its accompanying documents have not been and will not be despatched to Foreign Shareholders or into any jurisdiction outside Singapore.

### 2. INDICATIVE TIMETABLE OF KEY EVENTS

Entitled Shareholders and Purchasers should take note of the following important dates and times in respect of the Rights cum Warrants Issue:

<b>Event</b>	<b>Date and Time</b>
Despatch of the Offer Information Statement, the ARE and the PAL (as the case may be) to Entitled Shareholders	: 6 October 2017

Commencement of trading of “nil-paid” rights	:	6 October 2017 from 9.00 a.m.
Last date and time for splitting and trading of “nil-paid” rights	:	16 October 2017 at 5.00 p.m.
Last date and time for acceptance of and payment for Rights Shares with Warrants	:	23 October 2017 at 5.00 p.m. (9.30 p.m. for Electronic Applications)
Last date and time for acceptance of and payment for Rights Shares with Warrants by renounees	:	23 October 2017 at 5:00 p.m. (9.30 p.m. for Electronic Applications)
Last date and time for application and payment for Excess Rights Shares with Warrants	:	23 October 2017 at 5:00 p.m. (9.30 p.m. for Electronic Applications)
Expected date for issue of Rights Shares	:	30 October 2017
Expected date for issue of Warrants	:	30 October 2017
Expected date for crediting of Rights Shares with Warrants	:	31 October 2017
Expected date for refund of unsuccessful or invalid applications (if made through CDP)	:	31 October 2017
Expected date for the listing and commencement of trading of Rights Shares	:	31 October 2017 from 9.00 a.m.
Expected date for the listing and commencement of trading of Warrants (subject to there being an adequate spread of holdings of the Warrants to provide for an orderly market in the trading of the Warrants)	:	1 November 2017 from 9.00 a.m.

The above timetable is indicative only and is subject to change. As at the date of this announcement, the Company does not expect the above timetable to be modified. However, the Company may, upon consultation with its advisers and with the approval of the Sponsor and/or the SGX-ST, modify the timetable subject to any limitations under any applicable laws. In such an event, the Company will publicly announce the same through an SGXNET announcement to be posted on the website of the SGX-ST at <http://www.sgx.com>.

### **3. ACCEPTANCES OF PROVISIONAL ALLOTMENTS OF RIGHTS SHARES WITH WARRANTS AND (IF APPLICABLE) APPLICATION FOR EXCESS RIGHTS SHARES WITH WARRANTS**

Acceptances of provisional allotments of Rights Shares with Warrants and (if applicable) applications for Excess Rights Shares with Warrants may only be made:

- (a) in the case of Entitled Depositors, by way of the ARE through CDP, or by way of an Electronic Application through an ATM of a Participating Bank; or
- (b) in the case of Entitled Scripholders, by way of the PAL through the Share Registrar.

More information on the procedures for acceptance, payment, splitting, renunciation and applications for Rights Shares with Warrants and Excess Rights Shares with Warrants by Entitled Shareholders can be found in the Offer Information Statement, the ARE and the PAL.

#### **4. TRADING PERIOD FOR “NIL-PAID” RIGHTS SHARES WITH WARRANTS**

Trading for the provisional allotments of Rights Shares with Warrants on Catalist (the “**nil-paid rights**”) will commence from 9.00 a.m. on 6 October 2017 and will end at 5.00 p.m. on 16 October 2017. Entitled Depositors who sell their nil-paid rights during this period need not forward the ARE to the Purchasers as arrangements will be made by CDP for a separate application and acceptance form for Rights Shares with Warrants (the “**ARS**”) to be issued to the Purchasers.

Purchasers should note that CDP will, for and on behalf of the Company, send the Offer Information Statement and the ARS, by ordinary post and at the Purchasers’ own risk, to their respective Singapore addresses as maintained in the records of CDP.

The Offer Information Statement and its accompanying documents will not be despatched to Foreign Purchasers. Foreign Purchasers who wish to accept the provisional allotments of the Rights Shares with Warrants credited by CDP to their Securities Accounts should make the necessary arrangements with their Depository Agents or stockbrokers in Singapore. The Company further reserves the right to reject any acceptances of the provisional allotment of the Rights Shares with Warrants and/or any applications for excess Rights Shares with Warrants where it believes, or has reason to believe, that such acceptances or applications may violate the applicable legislation of any jurisdiction.

#### **5. COLLECTION OF THE OFFER INFORMATION STATEMENT**

Entitled Shareholders who do not receive the Offer Information Statement and its accompanying documents (the ARE or the PAL, as the case may be) may during the period up to 5.00 p.m. on 23 October 2017 (or such other time(s) and/or date(s) as may be announced from time to time by or on behalf of the Company) obtain copies of the documents from:

##### **In the case of Entitled Depositors:**

###### CDP

The Central Depository (Pte) Limited  
9 North Buona Vista Drive  
#01-19/20 The Metropolis  
Singapore 138588

##### **In the case of Entitled Scripholders:**

###### Share Registrar of the Company

Boardroom Corporate & Advisory Services  
Pte Ltd  
50 Raffles Place, #32-01  
Singapore Land Tower  
Singapore 048623

Purchasers who do not receive the ARS and the Offer Information Statement may obtain copies of the same from CDP (at the address stated above) during the period up to 5.00 p.m. on 23 October 2017 (or such other time(s) and/or date(s) as may be announced from time to time by or on behalf of the Company).

#### **6. GENERAL**

This announcement is qualified in entirety by, and should be read in conjunction with, the full text of the Offer Information Statement. Where appropriate, further details will be disclosed in subsequent announcements.

**By Order of the Board**

**3 October 2017**

---

*This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor") for compliance with the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalyst. The Sponsor has not verified the contents of this announcement.*

*This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.*

*The contact person for the Sponsor is Lance Tan, Director, Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).*